Tradipitant

Pre-clinicalActive

0 views this week 0 watching💤 Quiet

Interest: 20/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastroparesis

Conditions

Gastroparesis, Diabetic Gastroparesis

Trial Timeline

— → —

NCT ID

NCT04474990

About Tradipitant

Tradipitant is a pre-clinical stage product being developed by Vanda Pharmaceuticals for Gastroparesis. The current trial status is active. This product is registered under clinical trial identifier NCT04474990. Target conditions include Gastroparesis, Diabetic Gastroparesis.

What happened to similar drugs?

6 of 8 similar drugs in Gastroparesis were approved

Approved (6) Terminated (4) Active (2)

✅tadalafilEli LillyApproved

✅Mosapride + domperidoneSumitomo PharmaApproved

✅Cisapride + PlaceboJohnson & JohnsonApproved

✅TegaserodNovartisApproved

✅Immediate-release omeprazole + Delayed-release omeprazoleBausch HealthApproved

🔄TradipitantVanda PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04474990	Pre-clinical	Active	—	—	Gastroparesis
NCT06836557	Phase 3	Recruiting	Jan 9, 2024	Dec 1, 2025	Idiopathic Gastroparesis
NCT06138613	Phase 3	Active	Feb 27, 2023	Jun 30, 2026	Motion Sickness

Competing Products

19 competing products in Gastroparesis

See all competitors

Product	Company	Stage	Hype Score
tadalafil + tadalafil + placebo	Eli Lilly	Phase 2	35
Granisetron	Kyowa Kirin	Phase 2	27
tadalafil	Eli Lilly	Approved	35
Mosapride + domperidone	Sumitomo Pharma	Approved	39
Cisapride + Placebo	Johnson & Johnson	Approved	35
Cisapride + Placebo	Johnson & Johnson	Approved	35
Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet	AstraZeneca	Phase 2	27
Sitagliptin + Placebo	Merck	Phase 1	29
Tegaserod	Novartis	Approved	35
Reglan ODT	UCB	Pre-clinical	26
Hemin + Albumin	Recordati	Phase 2	32
CNSA-001 + Placebo	PTC Therapeutics	Phase 2	32
Immediate-release omeprazole + Delayed-release omeprazole	Bausch Health	Approved	37
Velusetrag + Placebo	Theravance Biopharma	Phase 2	29
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo	Theravance Biopharma	Phase 2	29
IW-9179 + Matching Placebo	Ironwood Pharmaceuticals	Phase 2	29
VLY-686 (Tradipitant)	Vanda Pharmaceuticals	Phase 2	25
Tradipitant	Vanda Pharmaceuticals	Phase 3	37
Tradipitant + Placebo + Open Label Tradipitant	Vanda Pharmaceuticals	Phase 3	30